The nine-year-old bull market in U.S. stocks has been dominated by growth and momentum plays, such as the popular FAANG group of stocks. These momentum stocks have significantly outperformed value stocks, and Oppenheimer analyst Ari Wald says there’s no reason for investors to be fearful of momentum stocks just because stock prices are near all-time highs. After nine years, a certain degree of caution is understandable, but Wald says price action has remained bullish. Wald and the Oppenheimer analyst team recently selected the best momentum stock to buy in each of nine different market sectors.
History has shown that investing in stocks is one of the easiest and most profitable ways to build wealth over the long-term. With a handful of notable exceptions, almost every member of the Forbes 400 list of the wealthiest people got there because they own a large block of shares in a public or private corporation. Although your beginning may be humble, this guide to investing in stocks will explain what stocks are, how you can make money from them, and much more.
Few professional investment managers make use of momentum investing, believing that individual stock picking based on an analysis of discounted cash flows and other fundamental factors tends to produce more predictable results, and is a better means of beating index performance over the long term. "As an investment strategy, it’s a thumb in the eye of the 'efficient market hypothesis' (EMH), one of the central tenets of modern finance," to quote a UCLA Anderson Review article, "Momentum Investing: It Works, But Why?" published on Oct. 31, 2018.
Books provide a wealth of information and are inexpensive compared to the costs of classes, seminars, and educational DVDs sold across the web. Here on the site we have a full list of 20 great stock trading books for investors to consider. My personal all-time favorite is How to Make Money in Stocks by William O’Neil, founder of CANSLIM Trading which is pictured below.
uniQure N.V. (QURE) jumped $6.10, or 9.4%, to $70.74 on 2.5 million shares Tuesday.  The move, on nearly 5x the stock's average volume, came on no news from the gene therapy company.  The stock, which had a steep ascent from around $28 to just under $70 in the first three months of the year, looks poised to resume the uptrend, as Tuesday's move broke it out above the March double-top.  Watch for $80-85 next.
Momentum investing usually involves a strict set of rules based on technical indicators that dictate market entry and exit points for particular securities. Momentum investors sometimes use two longer-term moving averages, one a bit shorter than the other, for trading signals. Some use 50-day and 200-day moving averages, for example. The 50-day crossing above the 200-day creates a buy signal. A 50-day crossing back below the 200-day creates a sell signal. A few momentum investors prefer to use even longer-term moving averages for signaling purposes.